BFM
XENE icon

Boothbay Fund Management’s Xenon Pharmaceuticals XENE Stock Holding History

Boothbay Fund Management’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-54,700
Closed -$836K – 2268
2021
Q3 		$836K Buy
54,700
+34,400
+169% +$598K 0.02% 855
2021
Q2 		$378K Buy
20,300
+20,128
+11,702% +$371K 0.01% 1150
2021
Q1 		$308K Buy
+172
New +$2.92K 0.01% 1175

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Boothbay Fund Management's XENE Position: Q1 2026 in Review

Boothbay Fund Management increased its Xenon Pharmaceuticals (XENE) stake by 658% in Q1 2026, buying an estimated $10.8M and bringing the position to 270,412 shares worth $15.7M. The position accounts for 0.2% of the portfolio, ranked #62.

Boothbay Fund Management first reported a position in XENE in Q2 2018 and has held it in 29 quarters since. 290 funds tracked by Wall St. Rank hold XENE as of Q1 2026.

  • Boothbay Fund Management held 270,412 shares of Xenon Pharmaceuticals worth $15.7M as of Q1 2026.
  • Boothbay Fund Management bought 234,731 Xenon Pharmaceuticals shares in Q1 2026, an estimated $10.8M.
  • Xenon Pharmaceuticals made up 0.2% of Boothbay Fund Management's portfolio in Q1 2026, its #62 holding.
  • Boothbay Fund Management first reported a position in Xenon Pharmaceuticals in Q2 2018 and has held it in 29 quarters since.
  • 290 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q1 2026.

Based on Boothbay Fund Management's 13F filing for Q1 2026, filed 15 May 2026.